Novel histone deacetylase inhibitors in the treatment of thyroid cancer
- PMID: 15897598
- DOI: 10.1158/1078-0432.CCR-03-0776
Novel histone deacetylase inhibitors in the treatment of thyroid cancer
Abstract
Histone deacetylases (HDAC) and histone acetyltransferases exert opposing enzymatic activities that modulate the degree of acetylation of histones and other intracellular molecular targets, thereby regulating gene expression, cellular differentiation, and survival. HDAC inhibition results in accumulation of acetylated histones and induces differentiation and/or apoptosis in transformed cells. In this study, we characterized the effect of two HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and m-carboxycinnamic acid bis-hydroxamide, on thyroid carcinoma cell lines, including lines originating from anaplastic and medullary carcinomas. In these models, both SAHA and m-carboxycinnamic acid bis-hydroxamide induced growth arrest and caspase-mediated apoptosis and increased p21 protein levels, retinoblastoma hypophosphorylation, BH3-interacting domain death agonist cleavage, Bax up-regulation, down-regulation of Bcl-2, A1, and Bcl-x(L) expression, and cleavage of poly(ADP-ribose) polymerase and caspase-8, -9, -3, -7, and -2. Transfection of Bcl-2 cDNA partially suppressed SAHA-induced cell death. SAHA down-regulated the expression of the apoptosis inhibitors FLIP and cIAP-2 and sensitized tumor cells to cytotoxic chemotherapy and death receptor activation. Our studies provide insight into the tumor type-specific mechanisms of antitumor effects of HDAC inhibitors and a framework for future clinical applications of HDAC inhibitors in patients with thyroid cancer, including histologic subtypes (e.g., anaplastic and medullary thyroid carcinomas) for which limited, if any, therapeutic options are available.
Similar articles
-
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.Clin Cancer Res. 2006 Sep 15;12(18):5570-7. doi: 10.1158/1078-0432.CCR-06-0367. Clin Cancer Res. 2006. PMID: 17000694
-
Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents.J Pharmacol Exp Ther. 2008 Jun;325(3):978-84. doi: 10.1124/jpet.108.137398. Epub 2008 Feb 29. J Pharmacol Exp Ther. 2008. PMID: 18310471
-
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.Cancer Res. 2001 Dec 1;61(23):8492-7. Cancer Res. 2001. PMID: 11731433
-
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.Nat Clin Pract Oncol. 2005 Mar;2(3):150-7. doi: 10.1038/ncponc0106. Nat Clin Pract Oncol. 2005. PMID: 16264908 Review.
-
Targeting histone deacetylases: development of vorinostat for the treatment of cancer.Epigenomics. 2010 Jun;2(3):457-65. doi: 10.2217/epi.10.20. Epigenomics. 2010. PMID: 22121904 Review.
Cited by
-
Epigenomics in Hurthle Cell Neoplasms: Filling in the Gaps Towards Clinical Application.Front Endocrinol (Lausanne). 2021 May 24;12:674666. doi: 10.3389/fendo.2021.674666. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34108939 Free PMC article. Review.
-
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.Cancer Res. 2009 Feb 15;69(4):1536-44. doi: 10.1158/0008-5472.CAN-08-3718. Epub 2009 Feb 10. Cancer Res. 2009. PMID: 19208833 Free PMC article.
-
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.J Clin Endocrinol Metab. 2009 Jan;94(1):164-70. doi: 10.1210/jc.2008-1631. Epub 2008 Oct 14. J Clin Endocrinol Metab. 2009. PMID: 18854394 Free PMC article. Clinical Trial.
-
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.J Surg Res. 2014 Jul;190(1):191-7. doi: 10.1016/j.jss.2014.02.042. Epub 2014 Feb 28. J Surg Res. 2014. PMID: 24679699 Free PMC article.
-
Thyroid cancer: emerging role for targeted therapies.Ther Adv Med Oncol. 2010 Jan;2(1):3-16. doi: 10.1177/1758834009352667. Ther Adv Med Oncol. 2010. PMID: 21789122 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous